{
  "docId": "019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "docSlug": "fef1528177829f37cded553f72a56b72",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 44,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Includes footnotes defining abbreviations and trial details.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ec7b-760b-b9a4-60ceb97e90d9/24",
  "deckHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "deckJsonHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9.json",
  "deckAnchorHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.368,
        "y": 0.885
      },
      "kind": "disclaimer",
      "text": "1. Prespecified pooled analysis of the MELODY Phase III trial... LAAB = long-acting antibody; RSV = respiratory syncytial virus; LTRI = lower respiratory tract infection; TSLP = thymic stromal lymphopoietin; ERS = European Respiratory Society",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "591b133c-e7a4-4c37-84c7-077afdcb1724",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.285,
        "x": 0.675,
        "y": 0.425
      },
      "kind": "list",
      "text": "Phase III severe asthma trials: NAVIGATOR - Sustained exacerbation rate reductions of 58% vs. placebo; DESTINATION - Sustained safety and efficacy over 104 weeks",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79b635e8-6162-4375-b7af-224a82f6e47a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.285,
        "x": 0.355,
        "y": 0.375
      },
      "kind": "list",
      "text": "EU approval - first single dose preventative option for RSV in broad infant population; Based on MELODY/MEDLEY clinical programme; 79.5% efficacy against medically attended LRTI; Efficacy through to day 151",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7eab29c2-652b-4b16-bece-4eaabd5f9960",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.032,
        "w": 0.455,
        "x": 0.368,
        "y": 0.148
      },
      "kind": "title",
      "text": "Leadership and breadth across biologics",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa4573b3-e9c1-42ce-95ab-c36ff7c63031",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.585,
        "x": 0.368,
        "y": 0.068
      },
      "kind": "title",
      "text": "BioPharmaceuticals: R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf1372d1-701b-464d-876d-78aa4a7341ee",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b8887859-5600-4d0c-be84-abe7170bd2cc",
      "evidence": "list/bullet: EU approval - first single dose preventative option for RSV in broad infant population; Based on MELODY/MEDLEY clinical programme; 79.5% efficacy against medically attended LRTI; Efficacy through to day 151",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}